The KDM8 antibody is a crucial tool for studying the lysine demethylase 8 (KDM8), also known as JMJD5. a member of the Jumonji C (JmjC) domain-containing protein family. KDM8 functions as a histone demethylase, primarily targeting H3K36me2. and plays a role in regulating gene expression, cell cycle progression, and metabolic pathways. It is implicated in cancer biology, particularly in tumor growth, angiogenesis, and hypoxia adaptation through interactions with HIF-1α. Researchers use KDM8 antibodies to detect protein expression levels, localization, and post-translational modifications in various experimental settings, including Western blotting, immunoprecipitation, immunofluorescence, and immunohistochemistry. These antibodies help elucidate KDM8's role in diseases, such as liver, breast, and colorectal cancers, where its dysregulation is linked to poor prognosis. Additionally, KDM8 antibodies aid in exploring its therapeutic potential as a target for epigenetic drugs. Validation of antibody specificity is critical, often achieved via knockout controls or siRNA-mediated knockdown. Understanding KDM8's molecular mechanisms through antibody-based research contributes to advancements in epigenetics, oncology, and drug development.